We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 26, 2021

Adverse Event Profile Differences Between Rituximab and Ocrelizumab

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Multiple Sclerosis (Houndmills, Basingstoke, England)
Adverse Event Profile Differences Between Rituximab and Ocrelizumab: Findings From the FDA Adverse Event Reporting Database
Mult. Scler. 2021 Jun 01;27(7)1066-1076, NG Caldito, A Shirani, A Salter, O Stuve

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading